Work

The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants

Year: 2014
Type: article
Abstract: To the editor: Approximately 90% of patients with primary myelofibrosis (PMF) harbor JAK2 (58%), CALR (25%), or MPL (7%) mutations.[1][1][⇓][2]-[3][3] CALR -mutated PMF patients are younger than their JAK2 -mutated counterparts, and they display higher platelet count, lower leukocyte count,
Source: Blood
Institution: Mayo Clinic
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: green
OpenAlex ID: W2076578191
FWCI: 14.12
Cites: 8
Cited by: 178
Related to: 10